Key result
Cardiac glycosides reduce worsening heart failure events in selected HFrEF patients.
Why the study?
Use of cardiac glycosides declined after modern prognostic heart failure therapies emerged, prompting a re-evaluation of their role following two clinical trials showing reduced worsening heart failure events in patients with HFrEF.
Do cardiac glycosides reduce the risk of worsening heart failure events in patients with heart failure with reduced ejection fraction?
Do cardiac glycosides reduce the risk of worsening heart failure events in patients with heart failure with reduced ejection fraction?
Recent trials suggest cardiac glycosides still have a specific role in reducing worsening heart failure events in selected patients with HFrEF.
Answers are grounded in this paper and cite their sources.
Supports specific role for cardiac glycosides in selected HFrEF patients; leaves open optimal integration with contemporary therapies.
Cardiac glycosides were the cornerstone of heart failure treatment for decades, but their use progressively declined after the introduction of modern prognostic medications. Two clinical trials now report that cardiac glycosides can reduce the risk of worsening heart failure events in patients with heart failure with reduced ejection fraction. These results do not mandate a paradigm shift but support a specific role for cardiac glycosides in selected patients.
No takes yet. Share an insight, caveat, or question.
Cannatà et al. (2026) conducted a review in Heart failure with reduced ejection fraction. Cardiac glycosides was evaluated on Worsening heart failure events. Cardiac glycosides can reduce the risk of worsening heart failure events in selected patients with heart failure with reduced ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: